Elise Van Caelenberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elise Van Caelenberg has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Arno Belpaire
Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium
2 shared publications - Nanja van Geel
Ghent University Hospital, Ghent, Belgium
2 shared publications - Reinhart Speeckaert
Department of Dermatology, Ghent University Hospital , Ghent
2 shared publications - Annelies Demeyer
Head and Skin Research Group, Ghent University, Ghent, Belgium
1 shared publication Arno Belpaire
Department of Head and Skin, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
1 shared publication- Marijn M. Speeckaert
Univeersiteit Gent, Gent, Belgium
1 shared publication
Latest Publications
- Open Access
- 3 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1648868
A meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle
A deeper understanding of the immune-based pathogenesis of alopecia areata is essential for the development of novel targeted therapies. Compared to cytokines, chemokines exhibit substantially higher serum concentrations, offering a more robust approach for large-scale immune profiling. However, the complexity of chemokine interactions presents challenges in defining their precise roles in AA. To explore these dynamics, we conducted a scoping review and meta-analysis of 46 original research articles examining chemokine expression in skin and blood samples from AA patients; meta-analysis was performed when three or more studies assessed the same chemokine in comparable groups. Th1-associated chemokines—including CXCL9, CXCL10, CCL5, and CXCL11—were consistently elevated in AA, reflecting the known IFN-γ–driven response. A distinct Th2 chemokine signature was also observed, with increased levels of CCL13, CCL17, CCL22, and CX3CL1. Additionally, elevated levels of CCL2, CCL3, CCL4 (monocyte/dendritic cell recruitment), and CCL11, CCL24, and CCL26 (eosinophil recruitment) suggest the involvement of immune pathways beyond classical T helper subsets. Meta-analysis confirmed significantly elevated serum levels of CXCL9 (p = 0.003), CXCL10 (p = 0.004), CXCL8 (p < 0.001), and CCL17 (p < 0.001). These findings reveal a complex chemokine profile in AA, dominated by Th1 activity but also implicating Th2 and other immune pathways, highlighting the potential benefit of broader immunomodulatory strategies to address the multifaceted immune dysregulation underlying the disease.
- 3 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1648868
Open AccessA meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle
A deeper understanding of the immune-based pathogenesis of alopecia areata is essential for the development of novel targeted therapies. Compared to cytokines, chemokines exhibit substantially higher serum concentrations, offering a more robust approach for large-scale immune profiling. However, the complexity of chemokine interactions presents challenges in defining their precise roles in AA. To explore these dynamics, we conducted a scoping review and meta-analysis of 46 original research articles examining chemokine expression in skin and blood samples from AA patients; meta-analysis was performed when three or more studies assessed the same chemokine in comparable groups. Th1-associated chemokines—including CXCL9, CXCL10, CCL5, and CXCL11—were consistently elevated in AA, reflecting the known IFN-γ–driven response. A distinct Th2 chemokine signature was also observed, with increased levels of CCL13, CCL17, CCL22, and CX3CL1. Additionally, elevated levels of CCL2, CCL3, CCL4 (monocyte/dendritic cell recruitment), and CCL11, CCL24, and CCL26 (eosinophil recruitment) suggest the involvement of immune pathways beyond classical T helper subsets. Meta-analysis confirmed significantly elevated serum levels of CXCL9 (p = 0.003), CXCL10 (p = 0.004), CXCL8 (p < 0.001), and CCL17 (p < 0.001). These findings reveal a complex chemokine profile in AA, dominated by Th1 activity but also implicating Th2 and other immune pathways, highlighting the potential benefit of broader immunomodulatory strategies to address the multifaceted immune dysregulation underlying the disease.
- Open Access
- 7 March 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 10, 100282
The AhR pathway is dysregulated in alopecia areata
- 7 March 2025
- Published by Elsevier in Journal of Translational Autoimmunity
- Vol. 10, 100282
Open AccessThe AhR pathway is dysregulated in alopecia areata
- Top Cited PapersOpen Access
- 3 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5225
Vitiligo: From Pathogenesis to Treatment
Recent advances in vitiligo have provided promising treatment options, particularly through understanding the immune-mediated mechanisms leading to depigmentation. The inflammatory components in both vitiligo (non-segmental) and segmental vitiligo have similarities. Both are believed to result from an immune-based destruction of melanocytes by anti-melanocyte-specific cytotoxic T cells. The JAK-STAT pathway is activated with IFN-γ as the crucial cytokine and Th1-associated chemokines such as CXCL9 and CXCL10 recruit immune cells towards vitiligo skin. Nonetheless, clear differences are also present, such as the localized nature of segmental vitiligo, likely due to somatic mosaicism and increased presence of poliosis. The differing prevalence of poliosis suggests that the follicular immune privilege, which is known to involve immune checkpoints, may be more important in vitiligo (non-segmental). Immunomodulatory therapies, especially those targeting the JAK-IFNγ pathway, are currently at the forefront, offering effective inhibition of melanocyte destruction by cytotoxic T cells. Although Janus Kinase (JAK) inhibitors demonstrate high repigmentation rates, optimal results can take several months to years. The influence of environmental UV exposure on repigmentation in patients receiving immunomodulating drugs remains largely underexplored. Nonetheless, the combined effect of phototherapy with JAK inhibitors is impressive and suggests a targeted immune-based treatment may still require additional stimulation of melanocytes for repigmentation. Identifying alternative melanocyte stimulants beyond UV light remains crucial for the future management of vitiligo.
- 3 September 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5225
Top Cited PapersOpen AccessVitiligo: From Pathogenesis to Treatment
Recent advances in vitiligo have provided promising treatment options, particularly through understanding the immune-mediated mechanisms leading to depigmentation. The inflammatory components in both vitiligo (non-segmental) and segmental vitiligo have similarities. Both are believed to result from an immune-based destruction of melanocytes by anti-melanocyte-specific cytotoxic T cells. The JAK-STAT pathway is activated with IFN-γ as the crucial cytokine and Th1-associated chemokines such as CXCL9 and CXCL10 recruit immune cells towards vitiligo skin. Nonetheless, clear differences are also present, such as the localized nature of segmental vitiligo, likely due to somatic mosaicism and increased presence of poliosis. The differing prevalence of poliosis suggests that the follicular immune privilege, which is known to involve immune checkpoints, may be more important in vitiligo (non-segmental). Immunomodulatory therapies, especially those targeting the JAK-IFNγ pathway, are currently at the forefront, offering effective inhibition of melanocyte destruction by cytotoxic T cells. Although Janus Kinase (JAK) inhibitors demonstrate high repigmentation rates, optimal results can take several months to years. The influence of environmental UV exposure on repigmentation in patients receiving immunomodulating drugs remains largely underexplored. Nonetheless, the combined effect of phototherapy with JAK inhibitors is impressive and suggests a targeted immune-based treatment may still require additional stimulation of melanocytes for repigmentation. Identifying alternative melanocyte stimulants beyond UV light remains crucial for the future management of vitiligo.